I think what we're more interested in is really addressing our biologics attachment rate going forward. In the second half of the year, what we've assumed is the biologic attach rate doesn't improve a

company_statement / Sep 15, 2026 / receipt

I think the thing that's exciting about EOS is the EOS insight, so the software we're putting on top of it, allowing us to integrate with the workflow surgically and seeing the post six months go live

company_statement / Sep 15, 2026 / receipt

I think part of the virtue of the valence platform is we do think it's easier to adopt and administer than some of the competitive, ultimately longer term because it's just a little bit simpler, spine

company_statement / Sep 15, 2026 / receipt

our goal objective this year to place around 20, 25 units and do that in kind of a limited launch way. I think a couple of the positives there are we're placing those in really kind of smaller, I'd sa

company_statement / Sep 15, 2026 / receipt

We'll obviously have a bigger sales force, more revenue than we do today, and can really put that to work straight away in a way that can be both top line-accretive and ebit-accretive to us pretty qui

ir_statement / Sep 15, 2026 / receipt

Build a high-performing, aligned sales force designed to scale and win

ir_statement / Sep 13, 2026 / receipt

EXPAND, ELEVATE & ENABLE SALES FORCE

ir_statement / Sep 13, 2026 / receipt

Entryway into leading, most prestigious institutions and KOL surgeons.

ir_statement / Sep 13, 2026 / receipt

Establishes ATEC rep presence in high-value strategic accounts

ir_statement / Sep 13, 2026 / receipt

Rods make ATEC rep integral to case execution, locking out competition and expanding hardware pull-through

ir_statement / Sep 13, 2026 / receipt

ADVANCING PRESENCE AND INFLUENCE IN JAPAN

ir_statement / Sep 13, 2026 / receipt

EARLY EXPERIENCE POSITIVE, WITH PTP SERVING AS KEY GROWTH LEVER FOR EXPANSION

ir_statement / Sep 13, 2026 / receipt